\u201cThe Atrandi Biosciences team is looking forward to sharing with the ASHG community the progress we and our collaborators have made in single-cell multiomics,\u201d said Rapolas \u017dilionis, PhD, Chief Scientific Officer at Atrandi Biosciences. \u201cOur proprietary Semi-Permeable Capsule technology is a versatile and highly scalable solution that enables multi-modal assays \u2013 starting with DNA and RNA together \u2013 in thousands to millions of individual cells per experiment.\u201d<\/p>\n Expanded Single-Cell DNA & RNA Co-Sequencing Early Access Program<\/b><\/p>\n Atrandi will also be sharing more information about its single-cell DNA & RNA co-sequencing<\/a> early access program. The new application was designed for high-throughput joint profiling of targeted DNA variants and 3\u2019 gene expression from the same cell. It supports a variety of sample input types and uses Atrandi\u2019s core SPC technology to process up to millions of cells in parallel. In an ASHG educational session, two collaborators will present preliminary data demonstrating how SPC technology is being applied to lineage tracing and CRISPR workflows.<\/p>\n Featured Presentations<\/b><\/p>\n Industry Education Session:<\/p>\n The Power of Simultaneous Single-Cell RNA and Genomic DNA Sequencing in CRISPR Experiments<\/b><\/p>\n Date \/ Time: <\/b>Wednesday, Oct. 15, 3:00 pm \u2013 4:00 pm ET<\/p>\n Location: <\/b>Room 204AB, Thomas M. Menino Convention & Exhibition Center, Boston<\/p>\n Advance Registration:<\/b> Seating is limited. Learn more about the session and reserve your seat here<\/a>.<\/p>\n Scientific Poster:<\/p>\n Next-Generation Karyotyping: WGA-Free Single-Cell CNV Profiling<\/b><\/p>\n Number: <\/b>Board 4095T<\/p>\n Presenter:<\/b> Rapolas \u017dilionis, PhD<\/p>\n Date \/ Time: <\/b>Thursday, Oct. 16, 2:30 pm \u2013 4:30 pm ET<\/p>\n Atrandi\u2019s patented SPC technology is transforming high-throughput single-cell research. SPCs are microcapsules that have a liquid core surrounded by a thin, crosslinked hydrogel shell with size-selective permeability. Small molecules such as salts, buffers, enzymes, primers, and antibodies can diffuse freely across the capsule shell, while cells, genomic DNA, and larger molecular complexes remain contained within. Practically, that means users can wash, exchange, and stage any biochemical reaction, all while preserving single-cell resolution. SPCs effectively combine the modularity of wells with the high throughput of droplets and let scientists run bulk-like reactions at single-cell resolution. SPCs are designed for flexibility, integrating seamlessly across cell types and workflows to unlock new opportunities in single-cell multiomics. Learn more at www.atrandi.com\/technology\/semi-permeable-capsules<\/a>.<\/p>\n About Atrandi Biosciences<\/b><\/p>\n Atrandi Biosciences is transforming single-cell genomic analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable, true single-cell multiomics. By simplifying complex workflows, Atrandi accelerates discoveries in cellular heterogeneity, clonal evolution, microbiome diversity, microbial ecology, and more. Headquartered in Vilnius, Lithuania, the company is empowering scientists worldwide to push the boundaries of biological science. Its name, meaning \u201cyou discover\u201d in Lithuanian, embodies the company\u2019s mission to enable researchers to uncover the unknown. For more information, visit www.atrandi.com<\/a>.<\/p>\n Atrandi Biosciences and the Atrandi Biosciences logo are registered trademarks of Atrandi Biosciences.<\/p>\n Contacts<\/b><\/p>\n Media Contact<\/b> 415-722-2129<\/p>\n![](\"https:\/\/mms.businesswire.com\/media\/20251008711345\/en\/2603701\/22\/Atrandi-Biosciences_logo.jpg\"\/){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20251008711345\/en\/2603701\/21\/Atrandi-Biosciences_logo.jpg\"\/){kind=logo}
<\/a><\/p>\n\n
Yuriy Baglaenko, PhD,<\/a> Cincinnati Children\u2019s Hospital Medical Center<\/li>\n<\/ul>\n\n
Rapolas \u017dilionis, PhD,<\/a> Atrandi Biosciences<\/li>\n<\/ul>\n
Andrew Noble<\/p>\n